Background: State-of-the-art cervical cancer prevention includes human papillomavirus (HPV) vaccination among adolescents and screening/treatment of cervical precancer (CIN3/AIS and, less strictly, CIN2) among adults. HPV testing provides sensitive detection of precancer but, to reduce overtreatment, secondary "triage" is needed to predict women at highest risk. Those with the highest-risk HPV types or abnormal cytology are commonly referred to colposcopy; however, expert cytology services are critically lacking in many regions. Methods: To permit completely automatable cervical screening/triage, we designed and validated a novel triage method, a cytologic risk score algorithm based on computer-scanned liquid-based slide features (FocalPoint, BD, Burlington, NC). We compared it with abnormal cytology in predicting precancer among 1839 women testing HPV positive (HC2, Qiagen, Germantown, MD) in 2010 at Kaiser Permanente Northern California (KPNC). Precancer outcomes were ascertained by record linkage. As additional validation, we compared the algorithm prospectively with cytology results among 243 807 women screened at KPNC (2016-2017). All statistical tests were two-sided. Results: Among HPV-positive women, the algorithm matched the triage performance of abnormal cytology. Combined with HPV16/18/45 typing (Onclarity, BD, Sparks, MD), the automatable strategy referred 91.7% of HPV-positive CIN3/AIS cases to immediate colposcopy while deferring 38.4% of all HPV-positive women to one-year retesting (compared with 89.1% and 37.4%, respectively, for typing and cytology triage). In the 2016-2017 validation, the predicted risk scores strongly correlated with cytology (P < .001). Conclusions: High-quality cervical screening and triage performance is achievable using this completely automated approach. Automated technology could permit extension of high-quality cervical screening/triage coverage to currently underserved regions.
Background: State-of-the-art cervical cancer prevention includes human papillomavirus (HPV) vaccination among adolescents and screening/treatment of cervical precancer (CIN3/AIS and, less strictly, CIN2) among adults. HPV testing provides sensitive detection of precancer but, to reduce overtreatment, secondary "triage" is needed to predict women at highest risk. Those with the highest-risk HPV types or abnormal cytology are commonly referred to colposcopy; however, expert cytology services are critically lacking in many regions. Methods: To permit completely automatable cervical screening/triage, we designed and validated a novel triage method, a cytologic risk score algorithm based on computer-scanned liquid-based slide features (FocalPoint, BD, Burlington, NC). We compared it with abnormal cytology in predicting precancer among 1839 women testing HPV positive (HC2, Qiagen, Germantown, MD) in 2010 at Kaiser Permanente Northern California (KPNC). Precancer outcomes were ascertained by record linkage. As additional validation, we compared the algorithm prospectively with cytology results among 243 807 women screened at KPNC (2016-2017). All statistical tests were two-sided. Results: Among HPV-positive women, the algorithm matched the triage performance of abnormal cytology. Combined with HPV16/18/45 typing (Onclarity, BD, Sparks, MD), the automatable strategy referred 91.7% of HPV-positive CIN3/AIS cases to immediate colposcopy while deferring 38.4% of all HPV-positive women to one-year retesting (compared with 89.1% and 37.4%, respectively, for typing and cytology triage). In the 2016-2017 validation, the predicted risk scores strongly correlated with cytology (P < .001). Conclusions: High-quality cervical screening and triage performance is achievable using this completely automated approach. Automated technology could permit extension of high-quality cervical screening/triage coverage to currently underserved regions.
Authors: Philip E Castle; Erin C Gutierrez; Sharon V Leitch; Courtney E Maus; Ray A McMillian; William A Nussbaumer; Laurence M Vaughan; Cosette M Wheeler; Patti E Gravitt; Mark Schiffman Journal: J Clin Microbiol Date: 2011-06-01 Impact factor: 5.948
Authors: Roosmarijn Luttmer; Lise M A De Strooper; Johannes Berkhof; Peter J F Snijders; Maaike G Dijkstra; Margot H Uijterwaal; Renske D M Steenbergen; Folkert J van Kemenade; Lawrence Rozendaal; Theo J M Helmerhorst; Rene H M Verheijen; W Abraham Ter Harmsel; W Marchien Van Baal; Peppino G C M Graziosi; Wim G V Quint; Daniëlle A M Heideman; Chris J L M Meijer Journal: Int J Cancer Date: 2015-09-14 Impact factor: 7.396
Authors: Warner K Huh; Kevin A Ault; David Chelmow; Diane D Davey; Robert A Goulart; Francisco A R Garcia; Walter K Kinney; L Stewart Massad; Edward J Mayeaux; Debbie Saslow; Mark Schiffman; Nicolas Wentzensen; Herschel W Lawson; Mark H Einstein Journal: Obstet Gynecol Date: 2015-02 Impact factor: 7.661
Authors: Louiza S Velentzis; Michael Caruana; Kate T Simms; Jie-Bin Lew; Ju-Fang Shi; Marion Saville; Megan A Smith; Sarah J Lord; Jeffrey Tan; Deborah Bateson; Michael Quinn; Karen Canfell Journal: Int J Cancer Date: 2017-10-05 Impact factor: 7.396
Authors: Mark Schiffman; Walter K Kinney; Li C Cheung; Julia C Gage; Barbara Fetterman; Nancy E Poitras; Thomas S Lorey; Nicolas Wentzensen; Brian Befano; John Schussler; Hormuzd A Katki; Philip E Castle Journal: J Natl Cancer Inst Date: 2018-05-01 Impact factor: 13.506
Authors: Nicolas Wentzensen; Barbara Fetterman; Philip E Castle; Mark Schiffman; Shannon N Wood; Eric Stiemerling; Diane Tokugawa; Clara Bodelon; Nancy Poitras; Thomas Lorey; Walter Kinney Journal: J Natl Cancer Inst Date: 2015-09-15 Impact factor: 13.506
Authors: F Xavier Bosch; Claudia Robles; Mireia Díaz; Marc Arbyn; Iacopo Baussano; Christine Clavel; Guglielmo Ronco; Joakim Dillner; Matti Lehtinen; Karl-Ulrich Petry; Mario Poljak; Susanne K Kjaer; Chris J L M Meijer; Suzanne M Garland; Jorge Salmerón; Xavier Castellsagué; Laia Bruni; Silvia de Sanjosé; Jack Cuzick Journal: Nat Rev Clin Oncol Date: 2015-09-01 Impact factor: 66.675
Authors: Mark Schiffman; John Doorbar; Nicolas Wentzensen; Silvia de Sanjosé; Carole Fakhry; Bradley J Monk; Margaret A Stanley; Silvia Franceschi Journal: Nat Rev Dis Primers Date: 2016-12-01 Impact factor: 52.329
Authors: Kanan T Desai; Brian Befano; Zhiyun Xue; Helen Kelly; Nicole G Campos; Didem Egemen; Julia C Gage; Ana-Cecilia Rodriguez; Vikrant Sahasrabuddhe; David Levitz; Paul Pearlman; Jose Jeronimo; Sameer Antani; Mark Schiffman; Silvia de Sanjosé Journal: Int J Cancer Date: 2021-12-06 Impact factor: 7.316
Authors: Pierre Vassilakos; Ania Wisniak; Rosa Catarino; Eveline Tincho Foguem; Christine Balli; Essia Saiji; Jean-Christophe Tille; Bruno Kenfack; Patrick Petignat Journal: Int J Gynecol Cancer Date: 2021-04-08 Impact factor: 3.437